| Vandetanib - Wikipedia, the free encyclopedia Vandetanib (rINN, trade name Caprelsa), also known as ZD6474, is an antagonist of the vascular endothelial growth factor receptor (VEGFR) and the epidermal growth ... Read More |
| Vandetanib Official FDA information, side effects and uses. Accurate, FDA approved Vandetanib information for healthcare professionals and patients - brought to you by Drugs.com. Read More |
| CAPRELSA (vandetanib) REMS Program | Advanced Medullary Thyroid ... Information on CAPRELSA (vandetanib), a kinase inhibitor, approved by the FDA for symptomatic or progressive medullary thyroid cancer treatment in patients with ... Read More |
| AstraZeneca completes enrollment in two pivotal Phase III studies ... AstraZeneca announced today that it has completed patient enrollment in two pivotal Phase III studies for vandetanib, the company’s investigational, once-daily oral ... Read More |
| (vandetanib) These highlights do not include all the information needed to use CAPRELSA safely and effec tively. See full prescribing information for CAPRELSA . Read More |
| FDA approves new treatment for rare form of thyroid cancer The U.S. Food and Drug Administration today approved vandetanib to treat adult patients with late-stage (metastatic) medullary thyroid cancer who are ineligible for ... Read More |
| Vandetanib: MedlinePlus Drug Information Vandetanib may cause QT prolongation (an irregular heart rhythm that can lead to fainting, loss of consciousness, seizures, or sudden death). Tell your ... Read More |
| Vandetanib (Zactima) | c-RET Inhibitor | Buy Vandetanib (Zactima ... Vandetanib (Zactima) is a VEGFR and EGFR antagonist and a tyrosine kinase inhibitor with IC50 of 60, 90, 40 nM for HUVEC proliferation, PC-9 cells and tyrosine kinase ... Read More |
| Vandetanib - National Cancer Institute - Comprehensive Cancer ... This page contains brief information about vandetanib and a collection of links to more information about the use of this drug, research results, and ongoing clinical ... Read More |
| AstraZeneca - FDA approves orphan drug vandetanib AstraZeneca today announced that the US Food and Drug Administration (FDA) approved the orphan drug vandetanib for the treatment of medullary thyroid cancer that ... Read More |
